0001415889-24-006165.txt : 20240301
0001415889-24-006165.hdr.sgml : 20240301
20240301175049
ACCESSION NUMBER: 0001415889-24-006165
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240223
FILED AS OF DATE: 20240301
DATE AS OF CHANGE: 20240301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Reents Scott T
CENTRAL INDEX KEY: 0001937048
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35565
FILM NUMBER: 24712000
MAIL ADDRESS:
STREET 1: 1 NORTH WAUKEGAN ROAD
CITY: NORTH CHICAGO
STATE: IL
ZIP: 60064
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AbbVie Inc.
CENTRAL INDEX KEY: 0001551152
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 320375147
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 NORTH WAUKEGAN ROAD
CITY: NORTH CHICAGO
STATE: IL
ZIP: 60064
BUSINESS PHONE: (847) 932-7900
MAIL ADDRESS:
STREET 1: 1 NORTH WAUKEGAN ROAD
CITY: NORTH CHICAGO
STATE: IL
ZIP: 60064
4
1
form4-03012024_050325.xml
X0508
4
2024-02-23
0001551152
AbbVie Inc.
ABBV
0001937048
Reents Scott T
1 N. WAUKEGAN ROAD
NORTH CHICAGO
IL
60064
false
true
false
false
EVP, CHIEF FINANCIAL OFFICER
0
Common Stock, $0.01 par value
2024-02-23
4
M
0
14140
61.36
A
41205
D
Common Stock, $0.01 par value
2024-02-23
4
S
0
14140
177.44
D
27065
D
Common Stock, $0.01 par value
2024-02-28
4
F
0
11634
178.99
D
15431
D
Option (Right to buy)
61.36
2024-02-23
4
M
0
14140
61.36
D
2018-02-16
2027-02-15
Common Stock
14140
17380
D
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $177.41 to $177.55, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.
T.O. Odutayo, attorney-in-fact for Scott T. Reents
2024-03-01